Dynavax Technologies PE Ratio 2006-2021 | DVAX

Current and historical p/e ratio for Dynavax Technologies (DVAX) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Dynavax Technologies PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Dynavax Technologies PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 19.70 0.00
2021-06-30 9.85 $-0.26 0.00
2021-03-31 9.83 $-0.81 0.00
2020-12-31 4.45 $-1.07 0.00
2020-09-30 4.32 $-1.37 0.00
2020-06-30 8.87 $-1.71 0.00
2020-03-31 3.53 $-1.84 0.00
2019-12-31 5.72 $-2.21 0.00
2019-09-30 3.58 $-2.41 0.00
2019-06-30 3.99 $-2.57 0.00
2019-03-31 7.31 $-2.54 0.00
2018-12-31 9.15 $-2.55 0.00
2018-09-30 12.40 $-2.36 0.00
2018-06-30 15.25 $-2.09 0.00
2018-03-31 19.85 $-1.87 0.00
2017-12-31 18.70 $-1.84 0.00
2017-09-30 21.50 $-1.95 0.00
2017-06-30 9.65 $-2.47 0.00
2017-03-31 5.95 $-2.81 0.00
2016-12-31 3.95 $-2.91 0.00
2016-09-30 10.49 $-3.05 0.00
2016-06-30 14.58 $-2.97 0.00
2016-03-31 19.24 $-3.02 0.00
2015-12-31 24.16 $-3.29 0.00
2015-09-30 24.54 $-3.44 0.00
2015-06-30 23.43 $-3.72 0.00
2015-03-31 22.43 $-2.02 0.00
2014-12-31 16.86 $-1.55 0.00
2014-09-30 14.30 $-1.60 0.00
2014-06-30 16.00 $-1.40 0.00
2014-03-31 18.08 $-3.20 0.00
2013-12-31 19.60 $-3.80 0.00
2013-09-30 11.90 $-4.00 0.00
2013-06-30 11.00 $-4.10 0.00
2013-03-31 22.20 $-4.10 0.00
2012-12-31 28.50 $-4.10 0.00
2012-09-30 47.60 $-3.30 0.00
2012-06-30 43.20 $-3.50 0.00
2012-03-31 50.30 $-3.50 0.00
2011-12-31 33.20 $-4.00 0.00
2011-09-30 18.60 $-5.10 0.00
2011-06-30 27.50 $-4.50 0.00
2011-03-31 27.60 $-7.00 0.00
2010-12-31 32.00 $-7.10 0.00
2010-09-30 18.30 $-13.00 0.00
2010-06-30 18.60 $-14.80 0.00
2010-03-31 13.00 $-10.40 0.00
2009-12-31 14.20 $-7.40 0.00
2009-09-30 18.20 $0.70 26.00
2009-06-30 12.90 $1.70 7.59
2009-03-31 6.40 $-0.80 0.00
2008-12-31 8.40 $-5.20 0.00
2008-09-30 14.20 $-9.00 0.00
2008-06-30 14.60 $-11.90 0.00
2008-03-31 19.60 $-14.90 0.00
2007-12-31 51.10 $-15.10 0.00
2007-09-30 42.90 $-16.50 0.00
2007-06-30 41.50 $-16.20 0.00
2007-03-31 54.40 $-16.70 0.00
2006-12-31 91.80 $-16.10 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.201B $0.047B
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86